Last $7.72 USD
Change Today +0.14 / 1.85%
Volume 542.7K
VSTM On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

verastem inc (VSTM) Snapshot

Open
$7.52
Previous Close
$7.58
Day High
$7.96
Day Low
$7.37
52 Week High
02/12/14 - $16.60
52 Week Low
01/22/15 - $6.87
Market Cap
255.9M
Average Volume 10 Days
860.5K
EPS TTM
$-1.88
Shares Outstanding
33.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERASTEM INC (VSTM)

verastem inc (VSTM) Related Bloomberg News

View More Bloomberg News

verastem inc (VSTM) Related Businessweek News

No Related Businessweek News Found

verastem inc (VSTM) Details

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. The company’s lead FAK inhibitor, VS-6063, is in a registration-directed trial in patients with mesothelioma; a Phase Ib trial in combination with weekly paclitaxel for patients with ovarian cancer; a Phase II study in patients with non-small cell lung cancer; and a Phase I trial in Japan in patients with solid tumors. It is also developing FAK inhibitor, VS-4718; and dual mTORC1/2 and PI3K inhibitor, VS-5584, which are in Phase I clinical trials in patients with advanced cancers. The company’s product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

30 Employees
Last Reported Date: 03/6/14
Founded in 2010

verastem inc (VSTM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $443.8K
Co-Founder, Executive Chairman and Chairman o...
Total Annual Compensation: --
Chief Medical Officer
Total Annual Compensation: $350.0K
Chief Business Officer
Total Annual Compensation: $314.7K
Compensation as of Fiscal Year 2013.

verastem inc (VSTM) Key Developments

Verastem, Inc. Doses First Patient in Phase 1 Clinical Trial Evaluating Vs-5584 in Combination with Vs-6063 in Mesothelioma

Verastem, Inc. announced dosing of the first patient in a new clinical trial evaluating the combination of VS-5584, its dual mTORC1/2 and PI3K inhibitor, in combination with VS-6063, the Company’s lead focal adhesion kinase (FAK) inhibitor, in patients with relapsed mesothelioma. The Phase 1 open-label, dose escalation and schedule finding study is designed to assess safety, pharmacokinetics, pharmacodynamics and initial observations of clinical activity. The study is expected to enroll up to 56 patients at clinical sites in the UK and US. VS-5584 is currently in a Phase 1 study in advanced solid tumors where the compound has been generally well tolerated and preliminary activity has been observed, including in mesothelioma. Some patients have been on study for over 6 months and the maximum tolerated dose of VS-5584 has not been reached. The combination clinical trial is supported by preclinical work demonstrating the synergistic activity of VS-6063 and VS-5584 in mesothelioma models in vitro and in vivo. In this preclinical research, the combination of VS-6063 and VS-5584 displayed synergistic reduction in cell viability based on multiple combination analysis models. When tested in vivo for reduction of mesothelioma tumor growth, VS-6063 and VS-5584 were each active as single agents and demonstrated synergistic antitumor efficacy when used in combination.

Verastem Announces Publication of Scientific Data for VS-5584 in Cancer Research

Verastem, Inc. announced that a paper, titled 'PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells,' has been published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research. The paper discusses results from preclinical research evaluating VS-5584, a highly potent, selective small molecule inhibitor of mTORC1/2 and Class I PI3K kinases, which preferentially targets cancer stem cells (CSCs) in vitro and in vivo. CSCs represent a subpopulation of cancer cells that have tumor-initiating capability, are particularly resistant to chemotherapy and can mediate tumor recurrence both locally and at metastatic sites. The study results demonstrated that VS-5584 is up to 30-fold more potent in inhibiting the proliferation and survival of CSCs compared to non-CSCs in solid tumor cell populations. VS-5584 preferentially diminished CSC levels in multiple mouse xenograft models of human cancer. Similarly, VS-5584 treatment ex vivo preferentially reduced CSCs in surgically resected breast and ovarian patient tumors. In contrast, chemotherapeutics such as paclitaxel, cisplatin and etoposide effectively targeted bulk tumor cells, but enriched CSCs. Mechanistic investigations revealed that knock down of PI3Ka, PI3Kß or mTOR alone was insufficient to decrease CSCs, while knock down of PI3Ka, PI3Kß and mTOR together effectively reduced CSCs mimicking the effect of VS-5584. Consistent with CSC ablation, VS-5584 delayed tumor re-growth following chemotherapy in xenograft models of small cell lung cancer. These data help to elucidate the mechanism of VS-5584 targeting CSCs and provide a strong rationale for the clinical development of VS-5584 in combination with chemotherapeutic agents targeting bulk tumor cells to achieve more durable clinical responses in cancer patients.

Verastem, Inc., 2015 Guidance/Update Call, Jan 08, 2015

Verastem, Inc., 2015 Guidance/Update Call, Jan 08, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSTM:US $7.72 USD +0.14

VSTM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSTM.
View Industry Companies
 

Industry Analysis

VSTM

Industry Average

Valuation VSTM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERASTEM INC, please visit www.verastem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.